<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05036954</url>
  </required_header>
  <id_info>
    <org_study_id>21-0045</org_study_id>
    <nct_id>NCT05036954</nct_id>
  </id_info>
  <brief_title>Observational Study on the Efficacy and Tolerance of EYEBRID Lenses</brief_title>
  <acronym>EYEBRID</acronym>
  <official_title>Observational Study on the Efficacy and Tolerance of EYEBRID Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Technical advances in lenses are continuous and materials are improved. We provide a&#xD;
      prospective longitudinal observational study evaluating the efficacy and safety of new&#xD;
      EyeBrid Excel hybrid lenses (LCS) in the treatment of severe ametropia and for patients with&#xD;
      corneal irregularities.&#xD;
&#xD;
      This study should include 60 patients for a period of three months. The aim of this work is&#xD;
      to assess the improvement in the best corrected visual acuity and the good tolerance of this&#xD;
      lens.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2021</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>tolerance assesment</measure>
    <time_frame>3 month</time_frame>
    <description>scale of discomfort when using contact lenses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of visual acuity</measure>
    <time_frame>3 month</time_frame>
    <description>measurement of visual acuity by the ETDRS charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment and quantification of complications</measure>
    <time_frame>3 month</time_frame>
    <description>note the number of abscesses</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Contact Lens Complication</condition>
  <arm_group>
    <arm_group_label>no arm</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EyeBrid Excel hybrid lenses</intervention_name>
    <description>new lenses</description>
    <arm_group_label>no arm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Contact lens wearers, cohort of 60 patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  o Wear rigid lenses and complain about their lenses (discomfort, loss, poor vision) or&#xD;
&#xD;
               -  Wear rigid lenses and have objective intolerances (damage to surfaces related to&#xD;
                  rigid lenses) or&#xD;
&#xD;
               -  Are new wearers of lenses and presenting a strong ametropia (Strong myopia from&#xD;
                  -5.00 to -30.00d, strong hyperopia from + 4.50d to + 30.00d, strong astigmatism&#xD;
                  from 2.50d to 12.00d), with or without presbyopia (Addition of 0.75d to 3.50d)&#xD;
&#xD;
          -  Any patient diagnosed with Keratoconus stages 1 to 3.&#xD;
&#xD;
          -  Be affiliated to the social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with contraindications to wearing contact lenses&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Any minor or over 80 years old&#xD;
&#xD;
          -  Any infection, inflammation or abnormality of the anterior segments&#xD;
&#xD;
          -  Progressive ocular disorder of the anterior segments for which the wearing of contact&#xD;
             lenses would be discouraged;&#xD;
&#xD;
          -  Use of systemic or ocular treatment products for which the wearing of contact lenses&#xD;
             would be discouraged;&#xD;
&#xD;
          -  History of any herpetic keratitis;&#xD;
&#xD;
          -  History of any refractive surgery or any irregular cornea (except in cases where the&#xD;
             contact lenses examined may be worn by a subject with an irregular cornea, suffering&#xD;
             from keratoconus or having undergone refractive surgery);&#xD;
&#xD;
          -  Slit lamp observations of greater than grade 1 gravity;&#xD;
&#xD;
          -  Vascularization of the cornea with a penetration greater than 1 mm;&#xD;
&#xD;
          -  Case of pathological dry eye;&#xD;
&#xD;
          -  When a subject has participated in a clinical trial on contact lenses or contact lens&#xD;
             care products within the past 30 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Claude Quintyn, MD, PhD</last_name>
    <phone>00 33 2 31 06 46 30</phone>
    <email>quintyn-jc@chu-caen.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Caen University Hospital</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean Claude QUINTYN, MD PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 12, 2021</study_first_submitted>
  <study_first_submitted_qc>September 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

